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Graphical abstract 
Screening open access compound libraries to identify novel inhibitors of the growth of the 
kinetoplastid parasite Crithidia fasciculata 
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 Highlights (3-5 bullet points, 85 characters max. per bullet point) 
 
 C. fasciculata is a low-cost non-human infectious model for kinetoplastid biology 
 >1000 compounds from open access libraries screened for C. fasciculata inhibition 
 Dose-response testing confirmed inhibitory activity 
 Several inhibitors share a 2-(pyridin-2-yl) pyrimidin-4-amine scaffold 
 
Abstract 
Diseases caused by the pathogenic kinetoplastids continue to incapacitate and kill hundreds of 
thousands of people annually throughout the tropics and sub-tropics. Unfortunately, in the 
countries where these neglected diseases occur, financial obstacles to drug discovery and 
technical limitations associated with biochemical studies impede the development of new, safe, 
easy to administer and effective drugs. Here we report the development and optimisation of a 
Crithidia fasciculata resazurin viability assay, which is subsequently used for screening and 
identification of anti-crithidial compounds in the MMV and GSK open access chemical boxes. 
The screening assay had an average Z’ factor of 0.7 and tolerated a maximum dimethyl 
sulfoxide concentration of up to 0.5%. We identified from multiple chemical boxes two 
compound series exhibiting nanomolar potency against C. fasciculata, one centred around a 5-
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nitrofuran-2-yl scaffold, a well-known moiety in several existing anti-infectives, and another 
involving a 2-(pyridin-2-yl) pyrimidin-4-amine scaffold which seems to have pan-kinetoplastid 
activity. This work facilitates the future use of C. fasciculata as a non-pathogenic and 
inexpensive biological resource to identify mode of action/protein target(s) of potentially pan-
trypanocidal potent compounds. This knowledge will aid in the development of new treatments 
for African sleeping sickness, Chagas disease and leishmaniasis.  
Keywords : Crithidia fasciculata, kinetoplastid, drug discovery 
 
Introduction 
The trypanosomatidae family comprises several genera, some of which undergo cyclical 
development in both vertebrate and invertebrate hosts. These include the mammalian infective 
Trypanosoma and Leishmania species, responsible for potentially fatal diseases in both humans 
and animals. About half a billion people dwelling in tropical and sub-tropical areas of the World 
are at risk of contracting these diseases, with more than 20 million people infected with the 
pathogens that cause them, resulting in extensive suffering and more than 100,000 deaths per 
year [1]. 
The treatment options for the neglected tropical diseases caused by these pathogens have 
always been limited to a few relatively ineffective drugs, most of which were discovered over 
50 years ago. These drugs have been reported to possess several drawbacks and limitations in 
their efficacy. For example, the conventional drugs for treating Human African 
Trypanosomiasis (HAT) such as Suramin, Pentamidine, Melarsoprol and Eflornithine vary in 
effectiveness depending on the stage of the disease and the trypanosome species involved, 
require long periods of administration and are associated with toxicities and drug resistance [2]. 
Chagas disease front-line drugs Nifurtimox and Benznidazole are associated with severe side 
effects, long treatment periods (>60 days) and variations in sensitivity of the parasites [3-4]. 
Miltefosine is currently the only oral treatment for visceral leishmaniasis (VL), but its clinical 
use has been limited due to its teratogenic effects and increasing reports of treatment failures 
[5]. AmBisome, previously considered effective against VL, requires intravenous 
administration, is very expensive and is associated with side effects. The lack of formulations 
for paediatric patients and pregnant women and the unavailability of these trypanosomatid 
drugs due to low production [6] are clear obstacles in terms of drug accessibility to the people 
who really need them. There is, therefore, an urgent demand to identify novel drug targets and 
develop new therapies for these neglected diseases. 
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One approach to drug discovery is through high throughput screening (HTS) of diverse 
compound collections for identification of active hits by whole cell screening. Although several 
efforts have been made, drug discovery through HTS for these trypanosomatid diseases has 
been a slow process. This has been due, among other reasons, to a requirement for expensive 
containment facilities and costly serum-containing media, essential for propagation of these 
parasites. These and other factors renders drug discovery through HTS for these parasites 
impractical in resource-limited countries where the burden of the disease is highest. 
Crithidia fasciculata is a non-mammalian infective lower trypanosomatid, which can be 
handled in a standard laboratory without specific biosafety issues. C. fasciculata has relatively 
fast growth kinetics and can be easily and inexpensively grown to high cell densities in liquid 
media, which can be fully defined and serum-free. C. fasciculata represents a very interesting 
model to study biological cellular and genetic processes unique to members of the family 
Trypanosomatidae. This kinetoplastid has a very similar cellular machinery and is 
phylogenetically related to the human pathogenic trypanosomatids (T. brucei, T. cruzi and 
especially Leishmania spp. with whom it is more closely related) and is easily amenable to 
molecular, genetic and biochemical analyses.  
Over the past few decades C. fasciculata has been utilised as a model system to study the 
biochemical, cellular, and genetic processes unique to members of the family 
Trypanosomatidae. This has allowed researchers to uncover cellular and/or biochemical 
processes that ultimately could be exploited for the development of novel therapies for the 
related pathogenic trypanosomatids [7-12]. 
Although it should be noted that C. fasciculate are unable to invade / and are non-pathogenic 
to mammalian cells, and certain aspects of their proteome and mitochondria are different 
compared to Leishmania, probably reflecting differences in their carbon-source usage [13]. 
 
Here we explore the use of C. fasciculata as a low-cost model organism in determining the 
anti-crithidial activities of compounds from collections known to have anti-parasitic activity. 
We repurposed the current Medicines for Malaria venture (MMV) Pathogen box 
(http://www.mmv.org/) and the GlaxoSmithKline (GSK) Tres Cantos anti-kinetoplastid 
chemical boxes to screen for compounds active against C. fasciculata. The MMV chemical 
box contains 402 diverse drug-like compounds selected with activity against diseases such as 
Chagas disease, malaria, HAT, tuberculosis and schistosomiasis [14]. The GSK anti-
kinetoplastid compounds are assembled into three boxes according to the organism they are 
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most active against i.e. L. donovani (Leish-Box), T. cruzi (Chagas-Box) and T. brucei (HAT-
Box), with each box containing ~200 compounds [15]. These chemical boxes have been 
assembled and all data made publically available (https://www.ebi.ac.uk/chemblntd) with the 
aim of facilitating and stimulating the drug discovery for these neglected diseases.  
 
Materials and methods  
Reagents 
All chemicals and reagents used in the experiments were purchased from Sigma-Aldrich. 
Parasites and cell culture  
The C. fasciculata promastigotes clone HS6 were grown at 27°C with gentle agitation in axenic 
serum-free defined media containing yeast extract (5 mg/mL), tryptone (4 mg/mL), sucrose (15 
mg/mL), triethanolamine (4.4 mg/mL) and Tween 80 (0.5%) and supplemented with 10 µg/mL 
of haemin. The parasites were sub-cultured every 2-3 days to ensure log growth phase for 
subsequent experiments. 
Compound libraries  
Chemical boxes were kindly provided by MMV and GSK Tres Cantos. The MMV pathogen 
box contained 402 chemicals representing compounds that were active against one or more of 
12 distinct pathogens (see https://www.pathogenbox.org/about-pathogen-box/supporting-
information). Individual compounds had only been tested to confirm activity against the 
pathogen for which the compounds were first reported to be active, and have not been tested 
against the other pathogens represented in the pathogen box. All compounds have been tested 
for cytotoxicity: typically, they were five-fold less potent against a human fibroblast cell line 
(MRC-5) than the pathogen (https://www.pathogenbox.org/about-pathogen-box/supporting-
information).  
The three GSK kineto boxes (Leish-Box, Chagas-Box and HAT-Box), with each box 
containing ~200 compounds assembled by Pena and his colleagues [15] as previously 
discussed, were donated by GSK Tres Cantos. The supplied information included details on 
the pathogen against which the compound had shown activity, compound cytotoxicity, as well 
as other useful data such compound ID, batch ID, trivial name, molecular weight, salt, and 
cLogP. More information about these compounds can be accessed online via ChEMBL-NTD 
(https://www.ebi.ac.uk/chemblntd). 
Both the MMV and the GSK compounds were supplied in 96-well plates, containing 10 μL of 
10 mM dimethyl sulfoxide (DMSO) solution of each compound. Each compound was then 
diluted with phosphate buffer saline (PBS) to a working concentration of 2.5 mM (DMSO, 
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25%) and aliquoted into multiple plates. The compounds were stored at -80°C and thawed at 
room temperature prior to use. Each of the 400 compounds was screened in quadruplicate at a 
concentration of 100 µM (DMSO, 0.5% final concentration) in 96-well plates.  
C. fasciculata viability assay optimization  
Although resazurin-reduction assay has been extensively used for screening drug susceptibility 
of various cell types, it has not yet been applied to Crithidia. Therefore, a number of conditions 
such as the growth kinetics of cells, maximum cell densities, the incubation period, the 
resazurin concentration and the DMSO concentrations had to be considered and optimised for 
the resazurin-reduction assay to work as a screening tool in this system. A stock solution of 
12.5 mg/mL resazurin in PBS was used in all assays. All fluorescence measurements in this 
study were performed with the Spectra Max Gemini XPS Microplate reader (Molecular 
Devices) with excitation and emission wavelengths of 560 nm and 590 nm. 
Multiplicative kinetics of C. fasciculata 
Cell densities of three replicate cultures starting at 1 x 103, 1 x 104 and 3 x 104 cells/mL were    
microscopically monitored and counted using a haemocytometer at 24 hour intervals, over 5 
days. A growth curve was plotted to estimate the maximum number of cells attainable in a 96-
well plate before stationary phase and possible cell death occur.  
Effect of time and volume on resazurin fluorescence development  
In order to determine the fluorescent development at different volumes of the dye and the 
incubation period, C. fasciculata choanomastigotes (5 x 104 cells/mL) were incubated in the 
presence of various resazurin volumes (5, 10, 15 or 20 µL of a 12.5 mg/mL stock) and 
monitored after every 1 hour for a period of 4 hours.  After 4 hours of incubation, the 
fluorescent signal became saturated and the less dye in the medium, the more rapidly it was 
completely reduced by the cells and became colourless and non-fluorescent. The experiments 
were performed twice and the results were averaged over eight replicate wells. 
Determining the relationship between cell density and the resazurin fluorescence 
To determine the relationship between cell density and the fluorescence signal, the parasites in 
the logarithmic phase of a stock suspension of 1 x106 cells/ml were serially diluted (100 µL) 
into 96-well plates followed by addition of 10 µL of resazurin. Plates were incubated at 27°C 
and fluorescence measured after every 1 hour for a period of 4 hours. The experiments were 
performed twice and the results were averaged over eight replicate wells. 
Determining the effect of DMSO concentrations on the assay signal 
90 µl of medium containing C. fasciculata choanomastigotes (5,000 cells/mL) was inoculated 
into a 96-well plate and incubated for 24 hours. 10 µL of various (0.5 – 9.0 % final) 
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concentrations of DMSO diluted in the medium were then added to the plates and further 
incubated for 24 hours. The experiments were performed twice and the results were averaged 
over eight replicate wells. 
Primary screening assays 
C. fasciculata choanomastigotes in the log phase of growth were diluted 1:20 in the axenic 
growth media, and 20 µL was counted using a hemocytometer. For anti-crithidial activity, 
compounds were added to the test plates with medium containing the parasites (density ~5 x 
104 cells/ml) to achieve a final compound and DMSO concentration of 100 µM and 0.5%, 
respectively. The controls on each plate included wells containing growth media with 0.5% 
DMSO without cells (positive control) and growth media with 0.5% DMSO with cells only 
(negative control). The activities of test compounds were normalized against controls from the 
same plate according to the following formula: activity (%) = [1 − (FCpd − FPos) / (FNeg − FPos)] 
×100, where FCpd corresponds to the emitted fluorescent signal expressed in arbitrary 
fluorescence units for the test compound, and FNeg and FPos correspond to the mean fluorescent 
signal of the negative and the positive control wells, respectively. For estimation of the hit 
confirmation rate, compounds were considered confirmed when the normalized anti-parasitic 
activity was equal to or greater than 80% (≥80%) at 100 µM concentration. 
Dose-response assessments of active compounds 
The compounds which showed ≥80% inhibition when tested at 100 µM concentration in at 
least one biological replicate were retested in 10-point dose response, two-fold serial dilution 
experiments starting at various compound concentrations with the parasites seeding density of 
~5 x 104 cells/mL. Wells containing the 0.5% DMSO growth media with no cells and 0.5% 
DMSO growth media with cells but no drug, served as 100% inhibition and 100% growth 
controls, respectively. 10 µL of the resazurin solution was added after 44 hours incubation and 
fluorescence development was determined after a total drug exposure time of 48 hours. The 
obtained fluorescence data was analysed with the graphic data analysis software GraFit 
(Erithacus Sofware) which calculated EC50 values by linear regression from the sigmoidal dose 
inhibition curves. Compounds which did and did not yield an EC50 value within the confines 
of the analysis parameters were simply expressed as the true active and false active compounds, 
respectively. A few compounds of interest, which had comparably low EC50 values were 
selected from the top ten lists, purchased from commercial sources (Sigma-Aldrich) and 
screened to finally confirm their activities.  EC50 was defined as the concentration of a 
compound required to decrease the C. fasciculata viability by 50% compared to those grown 
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in the absence of the test compound.  All experiments were performed twice, with each drug 
concentration in quadruplicate. For standardisation, EC50 values were converted to pIC50.  
 
Results and discussion 
Resazurin-reduction C. fasciculata cell-based assay optimization 
In order to determine the maximum cell numbers that could be used for developing the 
screening assay, the growth kinetics of C. fasciculata parasites growing in our formulated 
serum-free medium was analysed using the growth curve shown in Supplementary Figure 1. 
The parasites grew quite robustly under axenic conditions in vitro and reached the stationary 
phase after 3 days. Similar C. fasciculata growth kinetics for in vitro culture systems have been 
reported elsewhere [16-17].  The average generation time was determined according to the 
Popp and Lattorff [18] equation and gave an estimation of approximately 4.5 hours. The 
doubling time observed is shorter than the doubling time (6.8 hours) reported for T. brucei 
brucei bloodstream forms when grown in HMI-9 supplemented with 10% foetal calf serum [18] 
and 7 hours for some Leishmania species (S. Menzies, personal communication). 
A linear relationship was observed between the incubation time and the fluorescent 
development of resazurin reduction (Supplementary Figure 2). However, low dye 
concentrations gave relatively higher fluorescent signal as compared to higher concentrations.  
A similar independent relationship between resazurin concentration and the fluorescent signal 
have been previously reported in alternative assays [19-20]. This is due to quick reduction of 
small volumes of the dye by the cells or perhaps high concentrations of resazurin salts having 
an inhibitory effect on cell growth and metabolism. For higher cell inoculums, the fluorescent 
signal easily reached saturation within a few minutes when a 5% (w/v) (5 µL) dye concentration 
was used but a strong fluorescent signal after 4 hours incubation was obtained with 10% (10 
µL) resazurin. Therefore 10% resazurin was selected as an ideal dye concentration for all of 
the assays. 
Nevertheless, the dye was linearly reduced proportionally to the incubation period 
(Supplementary Figure 3). However, for high cell densities such as 8 x 107/mL and 4 x 
107/mL, the fluorescence signal reached saturation after 1 hour and 2 hrs incubation, 
respectively. However, after 4 hrs incubation, a very strong signal from 2 x 107 cells/mL gave 
the best maximum fluorescence to background signal ratio of 9:1. The reported signal to 
background ratio (S/B) is higher than the 3:1 obtained from T. b. gambiense but lower than that 
from T. b. rhodesience (15:1) in similar assays [20]. These differences could be attributed to 
variations in dehydrogenase activity responsible for metabolizing resazurin or reduced uptake 
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of the dye substrate among the parasites. Differences in the fluorescence analysers, 
concentrations of the dye used, as well as the composition of media used to culture these 
parasites could potentially also account for some of the variations observed. 
Since compounds library collections were diluted in DMSO, which is known to be toxic to 
cells at various concentrations, it was necessary to determine its effects on the viability of the 
C. fasciculata by exposing the parasites to various DMSO concentrations (Supplementary 
Figure 4). The C. fasciculata parasites were able to tolerate maximum DMSO concentrations 
of up to 0.5% with no significant decrease in fluorescent signal. This DMSO sensitivity is 
slightly higher than the 0.42% reported for bloodstream form T. b. brucei strain 427 by Sykes 
and Avery [18], but lower than the 1% reported for bloodstream forms of T. brucei strain 427 
and T. congolense STIB910 [21]. One possible factor that may have resulted in such different 
observations of DMSO sensitivities might be the media used in each of the protocols. Different 
culture media can have different constituents which may positively or negatively react with the 
DMSO effecting the viability and consequently the doubling times of the parasites. The use of 
water to dilute compounds have been observed to possess significant effects on the cell viability 
and EC50 value of the compounds possibly due to osmotic effect of water on cells and changes 
in the buffering capacity of the medium [19]. 
After optimizations, the assay performance and its capabilities to discriminate the activities of 
different compounds was evaluated by calculating the Z’ factor [22]. Statistically, the assay 
performed well with an average Z’ factor of 0.7 (a maximum plating cell density of 5 x 104 
cells/mL, 48 hrs incubation, 10% v/v resazurin and maximum of 0.5% DMSO). The 
distribution of Z’ factor (a Z’ factor between 1-0.5 is an acceptable for a robust assay) in a total 
of 100 randomly selected plates is shown (Figure 1). This showed that the assay was able to 
discriminate compounds with different levels of inhibition during the screening process. 
Screening the chemical boxes for anti-crithidial compounds 
Utilizing conditions established during optimization, the resazurin-based C. fasciculata assay 
was used to screen for anti-crithidial compounds from the open access MMV pathogen box 
and GSK Tres Cantos chemical boxes. 
Using an inhibition cut-off of ≥80%, the primary screening of the MMV pathogen box led to 
the identification of 91 (23%) compounds with inhibitory activities at 100 µM against C. 
fasciculata. The dose-response experiments of the 91 compounds revealed 72 (79%) were true 
active compounds, representing an overall hit rate of 18% (Figure 2). The profiles and in vitro 
anti-crithidial activities of all compounds in the MMV pathogen box are shown 
(Supplementary Table 1). Ten compounds were picked based upon their potency and 
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selectivity from these confirmed true active compounds (Table 1). The screening revealed 
compounds (1 and 6) with a common 2-(pyridin-2-yl) pyrimidin-4-amine chemical scaffold 
and also compound 9 containing a pyrazol (3, 4) pyrimidin-4-amine. Derivatives of the 
pyrimidin-4-amine scaffold have been previously studied for their inhibitory activities against 
various protein kinase and cytochrome 51(CYP51) enzymes [15, 23]. The potency of 
compound 1, a 2-pyridyl-4-aminopyrimidine derivative, is proposed to be due to it targeting 
methionine aminopeptidases in Plasmodium, and activity against all the three pathogenic 
kinetoplastids is also reported [14]. Of note, compounds 3, 4 and 5 all have ~10 nM EC50 values 
against Crithidia. Compound 5 bearing a diaminoquinazoline moiety known to target the 
dihydrofolate reductases, was also found to possess sub-micromolar inhibitory activity against 
asexual stage of P. falciparum parasites [14]. 
Using our predefined activity criteria (inhibition cut-off of ≥80%), the primary screening of a 
T. brucei GSK box identified a total of 66 (35%) compounds with inhibitory activities against 
C. fasciculata of which 42 (64%) were confirmed true active after retesting, representing an 
overall hit rate of 22% (Figure 2).  
The primary screening of T. cruzi and Leishmania boxes revealed 101 (46%) and 122 (67%) 
compounds with inhibitory activities against C. fasciculata, of which 68 (67%) and 89 (73%) 
were confirmed true active after retesting, representing overall hit rates of 31% and 49%, 
respectively (Figure 2). The enriched hits rate observed after querying the GSK boxes may 
suggest the commonality of the targets shared between C. fasciculata and the T. brucei, T. cruzi, 
and Leishmania species. The higher hit rate observed from the Leishmania box is not surprising 
given the greater likelihood of conserved targets between Leishmania and Crithidia since they 
are phylogenetically closer to each other. The profiles and in vitro anti-crithidial activities of 
all compounds in the GSK T. brucei, T. cruzi and Leishmania boxes are shown in 
Supplementary tables 2, 3 and 4, respectively. The profiles of the ten most potent molecules 
from the confirmed active compounds in each of the GSK T. brucei, T. cruzi and Leishmania 
boxes are shown in Tables 2, 3 and 4, respectively.  
The T. brucei GSK box revealed compound 14 contains exactly the same 2-(pyridin-2-yl) 
pyrimidin-4-amine scaffold as those highlighted above from the MMV box. Three compounds 
(11, 15 and 20) contained a common 5-nitrofuran-2-yl scaffold, while the other five had distinct 
structures (Table 2). The nitro-substituted aryl group derivatives (11, 13, 15 and 20) are 
potential substrates for type I nitroreductase enzymes, responsible in various parasites for 
metabolising compounds into toxic nitrile products [24]. We observed Nifurtimox possesses a 
nanomolar potency (pIC50: 7.8±0.003) against C. fasciculata which, as it undergoes the same 
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mode of action, suggests the functionality of type I nitroreductases in these parasites. However, 
as there are several nitro-heterocycles that have been shown to have a different mode of action 
[25], and with renewed interest in treating kinetoplastid diseases with nitro-drugs, such as 
Nifurtimox and Benznidazole [26], there is a call for further studies on the mode of action of 
the potent nitro-aromatic chemicals identified in these compound libraries. The 5-nitrofuran-
2-yl derivatives are also known to inhibit Mycobacterium tuberculosis H37RV [27].  
As there are no mammalian nitroreductase homologues, the 5-nitrofuran-2-yl derivatives are 
potentially useful in anti-parasitic therapy; however, it is well known that most nitro-aromatics 
are not well tolerated by the patients that take them and often they do not complete the 
therapeutic regime [5, 6]. 
Querying the T. cruzi box hits (Table 3) shows two more nitro-heterocyclic analogues (21 and 
22). The relatively simple compound 29, with a pIC50 above 6, harbours a 1, 2, 3-thiadiazole-
5-carboxamide moiety, which has been reported to have antifungal activity [28]. Of particular 
interest is compound 23 with a quinolin-8-ol moiety. The potency of compounds harbouring 
the quinolin-8-ol moieties against P. falciparum, C. parvum, and fungal species has been 
previously reported [29, 30]. Quinoline derivatives mefloquine, chloroquine and tafenoquine 
exhibit antimalarial activities as heme polymerase inhibitors, while sitamaquine has been 
reported for its anti-leishmanial activity. 
The Leishmania box revealed three nanomolar hits (31, 32 and 40) (Table 4) with the same 2-
(pyridin-2-yl) pyrimidin-4-amine and the highly structurally related 2-(imidazoyl) pyrimidin-
4-amine and (pyridin-2-yl) triazine-2-amine scaffolds, respectively. The heterocyclic pyridines 
and other pyridine fused ring systems are widely reported to associate with several biological 
activities [31].  
Drugs derived from the pyrimidin-4-amine chemical class such as posaconazole are reported 
to clear T. cruzi in mouse models by inhibiting sterol 14α-demethylase and consequently 
blocking sterol biosynthesis and therefore membrane formation [32-33]. Another well-known 
pyrimidine CYP51 inhibitor is a plant fungicide fenarimol reported to be effective against T. 
cruzi [34] as well as Leishmania [35]. Other studies have reported the inhibition of T. cruzi 
growth by 4-trifluoromethyl pyrimidine derivatives and a significant improvement in potency 
when the 5-pyrimidinyl group is replaced with 3-pyridinyl and the ring 1-ortho-chlorophenyl 
is replaced with a 4-trifluoromethylphenyl moiety [34, 35, 36]. Nonetheless, series of 2, 4-
diaminopyrimidines analogues have been previously investigated and found to have in vivo 
efficacy against Trypanosoma brucei in an acute mouse model [37]. 
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Collectively, the data presented here and reported elsewhere in the literature suggests that 2-
(pyridin-2-yl) pyrimidin-4-amine (or a structurally similar scaffold) can form the basis of a 
pan-anti-kinetoplastid compound series targeting the same process in different kinetoplastids.  
In conclusion, we have developed a C. fasciculata viability assay that overcomes the limitations 
of safety and cost issues associated with drug discovery research in pathogenic kinetoplastids. 
The commonality of biological and cellular process between C. fasciculata and related 
pathogenic kinetoplastids shows the usefulness of this study to identify attractive chemical 
scaffolds within the GSK Tres Cantos and MMV boxes, providing valuable information for 
future efforts in anti-pathogenic kinetoplastid drug development. 
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Figure 1. Distribution of   Z’ in a total of 100 plates randomly selected from the MMV (plates 
1-25) and; GSK T. brucei (plates 26-50), T. cruzi (plates 51-75) and Leishmania (plates 76-
100) boxes. 
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 Figure 2. The flow diagram used to identify and progress hits of the open access pathogen boxes including 
key criteria considered in the decision-making process. In this case, all the compounds that had inhibition of 
≥80% were progressed to dose-response experiments to determine their EC50 values. True active compounds 
are those that had a ≥80% inhibition and showed an EC50 in dose-response experiments. 
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 Table 1. Profiles of the top ten hits identified from screening of the MMV pathogen box.  
 
The cytotoxicity data and other relevant information of these compounds are found at 
(http://www.pathogenbox.org/about-pathogen-box/supportinginformation). pIC50 values are means of two 
independent assays, which varied < ±50%. 
 
 
  
Compound 
ID 
pEC50 cLogP  
 
Compound name  Mol wt 
 
Structure of the 
compound 
1 MMV0
21013 
7.4 ± 0.004 3.55 
 
N-cyclohexyl-6-cyclopropyl-
2-(pyridin-2-yl)pyrimidin-4-
amine 
294.40 
 
 
2 MMV2
72144 
7.7 ± 0.03 -0.27 
 
1-(3-methoxyphenyl)-5-
(methylsulfonyl)-1H-tetrazole 
254.27 
 
 
3 MMV6
88755 
8.0 ± 0.001 2.81 
 
(S)-2-nitro-6-((4-
(trifluoromethoxy)benzyl)oxy)
-6,7-dihydro-5H-imidazo[2,1-
][1,3]oxazine 
359.26 
 
 
4 MMV6
89243 
8.0 ± 0.003 4.26 
 
N-(4-(trifluoromethyl)phenyl)-
N-(1-(5-
(trifluoromethyl)pyridin-2-
yl)piperidin-4-yl)pyridin-3-
amine 
466.42 
 
 
5 MMV6
75968 
8.0 ± 0.005 2.31 
 
5-chloro-6-(((2,5-
dimethoxyphenyl)amino)meth
yl)quinazoline-2,4-diamine 
359.81 
 
 
6 MMV6
58988 
6.1 ± 0.01 3.93 
 
5-chloro-N,6-dimethyl-N-
phenethyl-2-(pyridin-2-
yl)pyrimidin-4-amine 
338.84 
 
 
7 MMV5
53002 
6.3 ± 0.1 -0.31 
 
3-((methylsulfonyl)methyl)-
2H-benzo[][1,4]oxazin-2-one 
239.25 
  
8 MMV6
88262 
 
7.0 ± 0.04 5.04 
 
2-methyl-6-nitro-2-((4-(4-(4-
(trifluoromethoxy)phenoxy)pi
peridin-1-yl)phenoxy)methyl)-
2,3-dihydroimidazo[2,1-
b]oxazole 
534.48 
 
 
9 MMV6
88470 
 
6.1 ± 0.02 3.12 
 
1-(2-(1-
(methylsulfonyl)piperidin-4-
yl)ethyl)-3-(naphthalen-1-
ylmethyl)-1H-pyrazolo[3,4-
d]pyrimidin-4-amine 
464.58 
 
 
10 MMV6
76445 
 
6.1 ± 0.01 2.71 
 
2-(((1-propyl-1H-
benzo[d]imidazol-2-
yl)methyl)amino)phenol 
281.35 
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Table 2. Profile of ten top hit compounds identified in the GSK T. brucei box 
 
 
Data on cytotoxicity and other information about these compounds is found on 
(https://www.ebi.ac.uk/chemblntd). pIC50 values are means of two independent assays, which varied < 
±50%. 
Compound ID pEC50 Cyto-
toxicity 
(pIC50)  
cLogP 
 
Compound name  Mol wt 
 
Structure of the 
compound 
11 TCMDC
-143074 
 
5.5 ± 0.3 <4.0 
 
3.422 
 
2-(4-chlorophenyl)-5-
(5-nitrofuran-2-yl)-
2H-tetrazole 
291.65 
 
 
12 TCMDC
-143457 
 
5.4 ± 0.01 <4.0 
 
1.21 
 
2-(3-(4-
(difluoromethoxy)-3-
methoxyphenyl)-
1,2,4-oxadiazol-5-
yl)acetonitrile 
281.22 
 
 
13 TCMDC
-143609 
 
5.4 ± 0.2 4.7 
 
1.881 
 
4-bromo-2-
nitrobenzonitrile 
227.02 
 
 
14 TCMDC
-143363 
 
5.3 ± 0.03 4.5 
 
2.772 
 
N-(5-cyclopropyl-
1H-pyrazol-3-yl)-6-
methyl-2-(pyrrolidin-
1-yl)pyrimidin-4-
amine 
284.37 
 
 
15 TCMDC
-143112 
 
5.3 ± 0.1 4.8 
 
2.654 
 
(2-
(diethylamino)thiazol
-5-yl)(5-nitrofuran-2-
yl)methanone 
295.32 
 
 
16 TCMDC
-143316 
 
5.1 ± 0.5 4.5 
 
3.74 
 
5-methyl-7-(2,4,5-
trichlorophenoxy)-
[1,2,4]triazolo[1,5-
]pyrimidine 
329.58 
 
 
17 TCMDC
-143172 
 
5.0 ± 1.0 <4.0 
 
4.29 
 
3-chloro-N-(5-
chlorobenzo[]oxazol
-2-yl)benzamide 
307.13 
 
 
18 TCMDC
-143460 
 
5.0 ± 0.7 <4.0 
 
2.383 
 
N-(4,5-dimethyl-1H-
pyrazol-3-yl)-1H-
pyrrolo[2,3-
b]pyridin-4-amine 
227.27 
 
 
19 TCMDC
-143079 
 
5.0 ± 0.04 <4.0 
 
1.358 
 
4-(benzylcarbamoyl)-
1,2-phenylene 
bis(methylcarbamate) 
357.36 
 
 
20 TCMDC
-143073 
 
5.0 ± 0.3 <4.0 
 
1.212 
 
3-(5-(5-nitrofuran-2-
yl)-2H-tetrazol-2-
yl)pyridine 
258.20 
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 Table 3. Profile of ten top hit compounds identified in the GSK T. cruzi box 
 
Compound 
ID 
pEC50 Cyto-
toxicity 
(pIC50) 
cLogP 
 
Compound name  Mwt 
 
Structure of the 
compound 
21 TCMDC
-143149 
 
5.9 ± 0.05 <4.0 
 
-0.242 
 
5-((allyloxy)methyl)-
2-nitro-5,6-
dihydrooxazolo[3,2-
][1,2,4]triazole 
226.19 
 
 
22 TCMDC
-143088 
 
5.6 ± 0.1 <4.0 0.432 
 
1-(1-methyl-3-nitro-
1H-1,2,4-triazol-5-
yl)piperidine 
211.22 
 
 
23 TCMDC
-143308 
 
5.7 ± 0.01 4.7 
 
2.799 
 
2-methyl-7-(pyridin-
2-ylamino)(pyridin-3-
yl)methylquinolin-8ol 
342.39 
 
 
24 TCMDC
-143593 
 
5.8 ± 0.03 <4.0 
 
3.005 
 
((1S,2S)-2-((bis 
pyridin-3-yl-methyl) 
amino)methyl)cyclopr
opyl)(3-methoxy 
phenyl)methanone 
387.47 
 
 
25 TCMDC
-143590 
 
5.7 ± 0.07 4.3 
 
3.947 
 
1-(4-(4-bromo-2-
chlorophenoxy)butyl)-
1H-imidazole oxalate 
419.66 
 
 
26 TCMDC
-143606 
 
5.6 ± 0.01 4.7 
 
2.666 
 
6-ethyl-7-propyl-
pyrido [2,3-] 
pyrimidine 
-2,4-diamine 
231.30 
 
 
27 TCMDC
-143622 
 
6.5 ± 0.02 4.3 
 
4.109 
 
2-(4-(4-((4-
chlorophenyl)sulfonyl
)piperazin-1-yl) 
phenoxy)-N,N-
dimethylethan-1-
amine 
423.96 
 
 
28 TCMDC
-143422 
 
6.2 ± 0.05 <4.0 
 
3.173 
 
(3aS,7aS)-2-(2-
fluorophenyl)-5-
(pyridin-3-yl) 
octahydro-1H-
pyrrolo[3,4-
c]pyridine .TFA 
411.39 
 
 
29 TCMDC
-143612 
 
6.3 ±0.003 4.4 
 
1.913 
 
N(cyclohexylmethyl) -
1,2,3-thiadiazole-5-
carboxamide 
225.31 
 
 
30 TCMDC
-143127 
 
5.7 ± 0.01 <4.0 
 
2.525 
 
(2-chloro-4-
(pyrrolidin-1-
yl)phenyl)(4-methyl-
1,4-diazepan-1-
yl)methanone 
321.85 
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Data on cytotoxicity and other information about these compounds is found on 
(https://www.ebi.ac.uk/chemblntd). pIC50 values are means of two independent assays, which varied < 
±50%. 
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 Table 4. Profile of ten top hit compounds identified in the GSK Leish box 
Compound ID pEC50 Cyto-
toxicity 
(pIC50) 
cLogP 
 
 
Compound name  Mol wt 
 
Compound structure 
31 TCMDC 
-143621 
6.9 ± 
0.01 
4.3 
 
3.7 
 
N-(3-methoxy 
phenyl)-6-methyl-2-
(pyridin-2-yl) 
pyrimidin-4-amine 
292.34 
 
 
32 TCMDC 
-143487 
6.8 ± 
0.003 
4.8 3.597 
 
6-cyclopropyl-2-(1-
methyl-1H-imidazol-
2-yl)-N-(2-methyl-
benzyl)pyrimidin-4-
amine 
433.44 
 
 
33 TCMDC 
-143239 
6.0 ± 
0.2 
<4.0 
 
3.648 
 
N-(6 ethyl 
benzo[d]thiazol-2-
yl)-4 morpholino-
picolinamide 
368.46 
 
 
34 TCMDC 
-143586 
6.0 ± 
0.02 
4.0 
 
3.005 
 
((1S,2S)-2-((bis 
(pyridin-2-yl 
methyl)amino)methyl
)cyclopropyl)(3-
methoxy 
phenyl)methanone 
387.47 
 
 
35 TCMDC 
-143375 
5.9 ± 
0.1 
<4.0 
 
4.188 
 
5-ethyl-N-(1-phenyl -
1H-imidazol-2-yl) 
thiophene-3-
carboxamide 
297.38 
 
 
36 TCMDC 
-143315 
 
5.6 ± 
0.06 
<4.0 
 
3.07 
 
2-(((1-butyl-1H-
tetrazol-5-yl) 
methyl)thio)-4,6-di-
methylnicotinonitril 
302.40 
 
 
37 TCMDC 
-143113 
 
5.5 ± 
0.2 
4.4 
 
3.856 
 
N-(4-(pyridin-2-
yl)thiazol-2-yl)-
1,2,3,4-
tetrahydronaphthalen
e-2-carboxamide 
335.43 
 
 
38 TCMDC 
-143358 
 
5.4 ± 
0.01 
<4.0 
 
3.349 
 
N-benzyl-2-((1-
phenyl-1H-
pyrazolo[3,4-
b]pyridin-3-
yl)oxy)acetamide 
358.39 
 
 
39 TCMDC 
-143252 
 
5.5 ± 
0.5 
<4.0 
 
4.289 
 
N-butyl-4-
isobutyramido-N-
phenylbenzamide 
338.44 
 
 
40 TCMDC 
-143218 
 
5.5 ± 
0.3 
5.0 
 
1.55 
 
4-(5-amino-3-phenyl-
1H-pyrazol-1-yl)-6-
(pyridin-2-yl)-1,3,5-
triazin-2-amine.TFA 
1242.5 
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Data on cytotoxicity and other information about these compounds is found on 
(https://www.ebi.ac.uk/chemblntd). pIC50 values are means of two independent assays, which varied < 
±50%. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
